Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Analyst
Adam Walsh
Period: Reporting periods mapped to calendar 2025 Q4 – 2026 Q1 (2 quarters).
- Questions
- 2on tracked calls
- Challenge rate
- 0%none of 2 questionsLimited sample
- Companies
- 1questioned at least once
- Reporting periods
- 2with questions
These figures cover the whole profile: every tracked question, all reporting periods.
How to read these numbers
Challenge rate is the share of questions that pushed back, pressed for specifics or questioned management’s assumptions. It describes how questions were asked on the calls tracked here; it does not measure whether any view turned out to be right.
Rounding. Rates are rounded to whole percentages, so a small share can show as 0% even when some questions were challenging. The count beside each rate is exact; “none of N questions” means no question was challenging.
No questions recorded. “—” means there is nothing to calculate: no questions were recorded for that period on the calls tracked here. It does not mean there was no activity.
Fewer than 3 questions. A company-level rate is withheld when fewer than 3 questions were recorded for that company; the questions are still counted everywhere else.
Small samples. Profiles with fewer than 10 questions are marked Limited sample.
Reporting periods. Questions are grouped by the calendar quarter each company’s fiscal reporting period maps to, not by the date of the call. Periods without a calendar mapping are listed separately under their fiscal label.
Questions asked
Grouped by company, most questions first. Open a company to read its questions, newest reporting period first.
Showing 2 of 2 questions from 1 company
INSMInsmed Incorporated2 questions · 2 reporting periods · 0 of 2 challenging
Calendar 2026 Q1
What will you need to see to be able to give more granular guidance going forward as we progress through the 2026 quarters?
Show response
Management emphasized conservative approach and said they will revisit guidance each quarter. Stated they are more focused on execution than higher estimates, noting the building blocks for long-term sustainable growth are in place.
Calendar 2025 Q4
With your earliest patients now approaching 6 months on therapy, can you share any aggregate persistence or refill data
Show response
CEO highlighted once-daily pill as very low treatment burden versus typical respiratory inhaled medicines. Phase 3 25 mg dose showed highly nominally statistically significant patient-reported improvement and preservation of lung function. Both factors expected to drive persistence even if symptomatic relief perception varies.
Challenge rate by company
Every company this analyst questioned, most questions first. A company-level rate is shown from 3 questions; below that it is withheld.
| Company | Questions | Challenge rate |
|---|---|---|
| INSM Insmed Incorporated | 2 | —Rate withheld: fewer than 3 questions |
- INSMInsmed Incorporated · 2 questions—rate withheld: under 3 questions
Activity by reporting period
Questions recorded for each calendar quarter that companies’ reporting periods map to (not the call date), with the challenge rate for that period. Periods inside the range with no questions are shown as “No questions recorded”.
| Calendar period | Questions | Challenge rate | Companies |
|---|---|---|---|
| 2025 Q4 | 1 | 0%none of 1 question | 1 |
| 2026 Q1 | 1 | 0%none of 1 question | 1 |
- 2025 Q41 question · challenge rate 0% (none of 1 question) · 1 company
- 2026 Q11 question · challenge rate 0% (none of 1 question) · 1 company
Topics
Topics tagged on this analyst’s questions.
- Guidance Reliability1
- Revenue Growth1
- Product Launch1
- Demand1